Joon Young Jang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joon Young Jang has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Jaeseok Yang
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
4 shared publications - Ji-Jing Yan
Transplantation Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
3 shared publications - Gwang-Min Lee
Department of Medicine, Graduate School, Seoul National University College of Medicine, Seoul, Republic of Korea
2 shared publications - Honglin Piao
Department of Medicine, Graduate School, Seoul National University College of Medicine, Seoul, Republic of Korea
2 shared publications - Beom Seok Kim
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
1 shared publication - Chan Hyuk Kim
Research Institute of Pharmaceutical Sciences, Seoul National University, Gwanak-gu, Seoul, Korea (the Republic of)
1 shared publication
Latest Publications
- 23 April 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (17) , 1928-1940
Selective depletion of ABO-responsive B cells by T-cell–engaging bispecific antibody conjugates for ABOi transplantation
Organ transplantation is a pivotal treatment for patients with organ failure. ABO-incompatible (ABOi) transplantation, developed to expand the donor pool, presents significant clinical challenges due to preexisting antibodies targeting ABO antigens on donor organs. Current therapies using broad B-cell depletion, such as rituximab, effectively reduce antibody-mediated rejection but increase infection risks. Therefore, there is a critical need for targeted methods to specifically eliminate ABO-responsive B cells. Here, we developed a novel bispecific antibody-ligand conjugate (BiALC) platform designed to selectively target ABO-responsive B cells. Using synthetic trisaccharide A antigens conjugated to T-cell–recruiting Fab fragments, our optimized hexameric construct, (A3-peg)2-αCD3, demonstrated enhanced affinity and potent cytotoxicity specifically against type A antigen–responsive B cells. Notably, BiALC maintained robust efficacy even in the presence of circulating anti-A antibodies. In murine models, (A3-peg)2-αCD3 selectively depleted A-responsive B cells without broadly affecting total immunoglobulin M–positive (IgM+) and IgG+ B-cell populations, preserving overall immune competence. Similarly, the human-compatible BiALC, (A3-peg)2-αhCD3, effectively and selectively depleted type A–responsive B cells from human peripheral blood mononuclear cells, with potency comparable with that of rituximab, while sparing total antibody-secreting cells. Overall, the BiALC strategy offers a promising antigen-specific approach to reduce rejection risks in ABOi transplantation without inducing broad immunosuppression through nonspecific pan–B-cell depletion, supporting its potential for clinical translation.
- 23 April 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (17) , 1928-1940
Selective depletion of ABO-responsive B cells by T-cell–engaging bispecific antibody conjugates for ABOi transplantation
Organ transplantation is a pivotal treatment for patients with organ failure. ABO-incompatible (ABOi) transplantation, developed to expand the donor pool, presents significant clinical challenges due to preexisting antibodies targeting ABO antigens on donor organs. Current therapies using broad B-cell depletion, such as rituximab, effectively reduce antibody-mediated rejection but increase infection risks. Therefore, there is a critical need for targeted methods to specifically eliminate ABO-responsive B cells. Here, we developed a novel bispecific antibody-ligand conjugate (BiALC) platform designed to selectively target ABO-responsive B cells. Using synthetic trisaccharide A antigens conjugated to T-cell–recruiting Fab fragments, our optimized hexameric construct, (A3-peg)2-αCD3, demonstrated enhanced affinity and potent cytotoxicity specifically against type A antigen–responsive B cells. Notably, BiALC maintained robust efficacy even in the presence of circulating anti-A antibodies. In murine models, (A3-peg)2-αCD3 selectively depleted A-responsive B cells without broadly affecting total immunoglobulin M–positive (IgM+) and IgG+ B-cell populations, preserving overall immune competence. Similarly, the human-compatible BiALC, (A3-peg)2-αhCD3, effectively and selectively depleted type A–responsive B cells from human peripheral blood mononuclear cells, with potency comparable with that of rituximab, while sparing total antibody-secreting cells. Overall, the BiALC strategy offers a promising antigen-specific approach to reduce rejection risks in ABOi transplantation without inducing broad immunosuppression through nonspecific pan–B-cell depletion, supporting its potential for clinical translation.
- Open Access
- 28 May 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (22) , eabg2237
Tissue-engineered vascular microphysiological platform to study immune modulation of xenograft rejection
Tissue-engineered vascular microphysiological platform is applicable for evaluating immune modulation of xenograft rejection.
- 28 May 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (22) , eabg2237
Open AccessTissue-engineered vascular microphysiological platform to study immune modulation of xenograft rejection
Tissue-engineered vascular microphysiological platform is applicable for evaluating immune modulation of xenograft rejection.
- Open Access
- 12 February 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (2) , e0246967
Suppressive effects of vitamin C-treated induced-regulatory T cells on heart allograft rejection under vitamin C-deficient or –sufficient conditions
Foxp3 stability of vitamin C-treated induced-regulatory T cells (V-iTregs) is superior to that of conventional iTregs (C-iTregs). However, the role of V-iTregs in allograft rejection under vitamin C-deficient conditions, such as those seen in humans, remains unclear. We aimed to elucidate the role of vitamin C treatment on generation and maintenance of iTregs from gulo knockout (Gulo-KO) mice as well as wild type (WT) mice, and in vitro and in vivo suppressive effects of V-iTregs on heart allograft rejection in either Gulo-KO or WT recipient mice. Conversion efficiency of iTregs was similar between C- and V-iTregs in both WT and Gulo-KO mice. V-iTregs from WT or Gulo-KO mice showed better in vitro Foxp3 stability than C-iTregs, although there was no difference between WT V-iTregs and Gulo-KO V-iTregs. Furthermore, V-iTregs from WT or Gulo-KO mice suppressed in vitro T cell proliferation better than C-iTregs. Heterotrophic heart transplantation from BALB/c mice to WT or vitamin C-deficient Gulo-KO C57BL/6J mice was performed following adoptive transfer of C- or V-iTregs. V-iTregs as well as C-iTregs prolonged heart allograft survival in WT and Gulo-KO mice. However, there was no difference between the C- and V-iTreg groups. Supplementation of low- or high-dose vitamin C did not induce significant changes in heart allograft survival in Gulo-KO recipients that had received V-iTregs. In conclusion, V-iTregs do not exert better suppressive effects on heart allograft survival than C-iTregs in either WT or vitamin C-deficient recipients.
- 12 February 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (2) , e0246967
Open AccessSuppressive effects of vitamin C-treated induced-regulatory T cells on heart allograft rejection under vitamin C-deficient or –sufficient conditions
Foxp3 stability of vitamin C-treated induced-regulatory T cells (V-iTregs) is superior to that of conventional iTregs (C-iTregs). However, the role of V-iTregs in allograft rejection under vitamin C-deficient conditions, such as those seen in humans, remains unclear. We aimed to elucidate the role of vitamin C treatment on generation and maintenance of iTregs from gulo knockout (Gulo-KO) mice as well as wild type (WT) mice, and in vitro and in vivo suppressive effects of V-iTregs on heart allograft rejection in either Gulo-KO or WT recipient mice. Conversion efficiency of iTregs was similar between C- and V-iTregs in both WT and Gulo-KO mice. V-iTregs from WT or Gulo-KO mice showed better in vitro Foxp3 stability than C-iTregs, although there was no difference between WT V-iTregs and Gulo-KO V-iTregs. Furthermore, V-iTregs from WT or Gulo-KO mice suppressed in vitro T cell proliferation better than C-iTregs. Heterotrophic heart transplantation from BALB/c mice to WT or vitamin C-deficient Gulo-KO C57BL/6J mice was performed following adoptive transfer of C- or V-iTregs. V-iTregs as well as C-iTregs prolonged heart allograft survival in WT and Gulo-KO mice. However, there was no difference between the C- and V-iTreg groups. Supplementation of low- or high-dose vitamin C did not induce significant changes in heart allograft survival in Gulo-KO recipients that had received V-iTregs. In conclusion, V-iTregs do not exert better suppressive effects on heart allograft survival than C-iTregs in either WT or vitamin C-deficient recipients.
- 4 May 2018
- Published by Elsevier in Transplantation Proceedings
- Vol. 50 (4) , 1056-1062
VDJ Gene Usage of B Cell Receptors in Peripheral Blood of ABO-incompatible Kidney Transplantation Patients
- 4 May 2018
- Published by Elsevier in Transplantation Proceedings
- Vol. 50 (4) , 1056-1062
VDJ Gene Usage of B Cell Receptors in Peripheral Blood of ABO-incompatible Kidney Transplantation Patients